The U.S. Food and Drug Administration’s Sentinel Initiative has made important strides towards developing a valuable tool that can actively monitor the safety of medical products. Productive and broad collaboration among stakeholders from public and private institutions has been instrumental to this success. Since the Initiative’s inception, patient and consumer organizations have provided valuable perspectives and input into Sentinel.
On March 1, the Engelberg Center hosted an expert workshop, “Patients and Consumer Engagement in FDA’s Sentinel Initiative,” to explore opportunities for further engagement of these stakeholders in the Sentinel Initiative. This meeting brought together representatives from patient and consumer advocacy organizations and FDA to do the following:
- Provide patients and consumers with an overview of the Sentinel Initiative;
- Discuss opportunities for further patient and consumer engagement; and
- Discuss concrete next steps for evolving patient and consumer engagement.
Agenda
-
March 1
-
Welcome and Overview
-
Sentinel: Past, Present, and Future
Rachel Sherman Principal, Drug and Biological Drug Products - Greenleaf Health LLC -
Overview of the Mini-Sentinel Pilot
Richard Platt Professor and Chair, Department of Population Medicine - Harvard Pilgrim Health Care Institute -
Moderated Question and Answer
-
Facilitating Patient and Consumer Engagement
Bray Patrick-Lake Director of Patient Engagement - Duke Clinical and Translational Science AwardMyrl Weinberg Chief Executive Officer - National Health Council -
Furthering Initiatives for Patient and Consumer Engagement
Rachel Sherman Principal, Drug and Biological Drug Products - Greenleaf Health LLCRichard Platt Professor and Chair, Department of Population Medicine - Harvard Pilgrim Health Care InstituteBray Patrick-Lake Director of Patient Engagement - Duke Clinical and Translational Science Award -
Closing Remarks and Adjournment
-